Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Jul 21, 2006; 12(27): 4338-4344
Published online Jul 21, 2006. doi: 10.3748/wjg.v12.i27.4338
Published online Jul 21, 2006. doi: 10.3748/wjg.v12.i27.4338
No. | Age(yr) | Sex | Staging | Histological grading | Invasion | Survival time (wk) | ||
Vessel | Nerve | Lymph | ||||||
1 | 61 | Female | IVa | Adenosquamous | Yes | No | Yes | 16.85 |
2 | 50 | Male | IVb | Well differentiated | Yes | Yes | Yes | 27.28 |
3 | 56 | Male | IVb | Poorly differentiated | Yes | No | Yes | 4.85 |
4 | 54 | Male | IVa | Well differentiated | Yes | No | No | 56.57 |
5 | 46 | Male | IVb | Adenosquamous | Yes | No | Yes | 7.71 |
6 | 53 | Male | IVa | Well differentiated | Yes | No | Yes | 42.14 |
7 | 64 | Male | IVa | Poorly differentiated | Yes | No | Yes | 7.28 |
8 | 66 | Male | IVb | Poorly differentiated | Yes | No | Yes | 7.00 |
9 | 72 | Male | IVb | Unclassified | No | No | Yes | 20.14 |
10 | 64 | Female | IVb | Unclassified | Yes | Yes | Yes | 7.14 |
11 | 49 | Male | IVb | Well differentiated | Yes | No | No | 15.57 |
12 | 53 | Male | III | Poorly differentiated | Yes | No | Yes | 242.85 |
13 | 53 | Female | IVa | Well differentiated | Yes | No | No | 2.00 |
14 | 62 | Male | IVb | Adenosquamous | Yes | Yes | Yes | 3.00 |
15 | 56 | Male | II | Poorly differentiated | Yes | No | Yes | 30.71 |
16 | 55 | Male | IVb | Moderately differentiated | Yes | No | Yes | 72.57 |
17 | 68 | Male | IVb | Moderately differentiated | Yes | Yes | Yes | 32.00 |
18 | 72 | Female | IVb | Poorly differentiated | Yes | No | No | 18.57 |
19 | 65 | Female | IVb | Well differentiated | Yes | Yes | Yes | 20.85 |
20 | 52 | Male | IVa | Moderately differentiated | Yes | Yes | Yes | 36.71 |
21 | 53 | Male | IVb | Unclassified | Yes | No | No | 27.14 |
22 | 66 | Male | IVb | Moderately differentiated | Yes | Yes | Yes | 10.42 |
23 | 49 | Male | IVb | Well differentiated | No | Yes | Yes | 67.71 |
24 | 56 | Male | IVb | Adenosquamous | Yes | No | Yes | 10.00 |
25 | 41 | Male | IVb | Moderately differentiated | No | Yes | No | 47.14 |
26 | 67 | Female | IVb | Poorly differentiated | No | No | Yes | 118.28 |
27 | 63 | Male | IVa | Unclassified | Yes | Yes | Yes | 73.85 |
28 | 39 | Female | IVa | Well differentiated | Yes | Yes | Yes | 30.42 |
29 | 44 | Male | IVb | Unclassified | Yes | Yes | Yes | 18.71 |
30 | 60 | Female | IVb | Poorly differentiated | Yes | No | Yes | 75.71 |
31 | 40 | Male | III | Poorly differentiated | Yes | No | Yes | 26.57 |
32 | 62 | Male | IVb | Unclassified | No | No | Yes | 40.00 |
33 | 43 | Female | IVb | Moderately differentiated | No | Yes | Yes | 29.42 |
34 | 70 | Male | IVa | Unclassified | Yes | No | Yes | 79.42 |
35 | 63 | Female | III | Unclassified | No | No | No | 80.71 |
36 | 61 | Male | IVb | Moderately differentiated | No | Yes | Yes | 77.28 |
37 | 48 | Male | III | Unclassified | No | No | No | 94.00 |
38 | 55 | Male | IVb | Moderately differentiated | Yes | Yes | Yes | 12.14 |
39 | 50 | Female | IVb | Moderately differentiated | No | Yes | Yes | 40.14 |
40 | 39 | Male | IVb | Adenosquamous | Yes | No | Yes | 9.14 |
41 | 58 | Male | IVb | Well differentiated | Yes | Yes | Yes | 70.42 |
42 | 40 | Female | III | Moderately differentiated | No | Yes | No | 17.42 |
43 | 36 | Female | IVb | Well differentiated | No | Yes | Yes | 35.14 |
44 | 75 | Male | IVb | Poorly differentiated | Yes | No | Yes | 22.14 |
45 | 40 | Male | III | Well differentiated | No | Yes | Yes | 3.42 |
46 | 52 | Male | IVa | Adenosquamous | No | Yes | Yes | 49.00 |
47 | 49 | Male | IVb | Moderately differentiated | No | Yes | Yes | 27.42 |
48 | 63 | Male | IVb | Well differentiated | Yes | Yes | Yes | 18.28 |
49 | 50 | Male | IVb | Adenosquamous | Yes | Yes | Yes | 35.00 |
50 | 56 | Male | III | Poorly differentiated | Yes | No | Yes | 41.14 |
51 | 61 | Male | IVb | Poorly differentiated | Yes | No | No | 3.00 |
52 | 58 | Male | IVb | Well differentiated | Yes | No | Yes | 13.00 |
53 | 55 | Female | IVb | Well differentiated | Yes | Yes | Yes | 67.85 |
54 | 55 | Female | IVb | Poorly differentiated | No | Yes | Yes | 40.85 |
55 | 50 | Male | nd | Well differentiated | Yes | No | Yes | 10.71 |
56 | 38 | Male | IVb | Well differentiated | Yes | Yes | Yes | 27.85 |
57 | 46 | Female | nd | Well differentiated | Yes | Yes | Yes | 9.71 |
58 | 43 | Male | IVb | Well differentiated | Yes | No | Yes | 65.00 |
59 | 54 | Male | IVa | Well differentiated | No | No | No | 9.14 |
60 | 42 | Male | IVb | Moderately differentiated | No | Yes | Yes | 7.14 |
61 | 34 | Male | IVa | Well differentiated | Yes | Yes | Yes | 9.00 |
62 | 61 | Female | IVa | Unclassified | No | No | Yes | 89.14 |
63 | 62 | Female | IVb | Poorly differentiated | Yes | Yes | Yes | 45.28 |
64 | 51 | Male | IVa | Well differentiated | Yes | Yes | Yes | 55.42 |
65 | 46 | Male | IVa | Poorly differentiated | Yes | Yes | Yes | 18.71 |
Gene/marker | Band | Primer sequence (5’-3’) |
D22S283 | 22q12.3 | 5’ ACC AAC CAG CAT CAT CAT 3’ 5’ AGC TCG GGA CTT TCT GAG 3’ |
D22S423 | 22q13.1-13.2 | 5’ TGC AAA CTC AGC CTG GA 3’ 5’ ACC AAC TGA CTC GTT TAG GTC AT 3’ |
D22S274 | 22q13.3 | 5’ GTC CAG GAG GTT GAT GC 3’ 5’ AGT GCC CAT TTC TCA AAA TA 3’ |
NF2 | 22q12.2 | 5’ AAG AGC AAG CAT CTG CAG GA 3’ 5’ TGG TAT TGT GCT TGC TGC TG 3’ |
TIMP3 | 22q12.3 | 5’ TGT CTC TGG ACC GAC ATG CT 3’ 5’ TGG CGC TCA GGG ATC TGT G 3’ |
ST13 | 22q13.2 | 5’ GTT ACA CTA TTT AAG AGC TGA AT 3’ 5’ GGT CTT CTA CTT AGA AAA ACC TA 3’ |
TOB2 | 22q13.2-q13.31 | 5’ GAA GAC ACC CCT TTG TGG AA 3’ 5’ TCT GTG GTC TTG GGT GCT C 3’ |
BIK | 22q13.31 | 5’ ATG ACC ACT GCC CTG GAG 3’ 5’ CTA AAC ACA GGC CAC AGT TAA CC 3’ |
TP | 22q13.33 | 5’ GGG GCT CAA GTC GCG AGG 3’ 5’ CCT GCG GGG ATG CCT GAC 3’ |
β-actin (Reference) | 7p15-p12 | 5’ TCA CCC ACA CTG TGC CCA TCT ACG A 3’ 5’ CAG CGG AAC CGC TCA TTG CCA ATG G 3’ |
GAPDH (Reference) | 12p13 | 5’ ACA GTC CAT GCC ATC ACT GCC 3’ 5’ GCC TGC TTC ACC ACC TTC TTG 3’ |
Variables | Categories | Univariate analysis | Multivariate analysis | ||
P-value | HR (95% CI) | P-value | HR (95% CI) | ||
Stage | IVa + IVb vs II + III | NS | 1.560 (0.660-3.690) | ||
Histology | Poorly vs Unclassified | NS | 1.152 (0.507-2.619) | ||
Moderate vs Unclassified | NS | 0.994 (0.473-2.087) | |||
Well diff vs Unclassified | NS | 0.929 (0.429-2.013) | |||
Vessel invasion | Yes vs No | 0.021 | 2.080 (1.120-3.877) | 0.042 | 1.911 (1.022-3.571) |
Nerve invasion | Yes vs No | NS | 1.328 (0.770-2.293) | ||
Lymphatic invasion | Yes vs No | NS | 1.591 (0.716-3.536) | ||
TP | Deletion vs Normal | NS | 0.791 (0.314-1.997) | ||
Amplification vs Normal | NS | 1.034 (0.576-1.857) | |||
D22S274 | Deletion vs Normal | NS | 1.186 (0.625-2.250) | ||
Amplification vs Normal | NS | 0.869 (0.439-1.718) | |||
BIK | Deletion vs Normal | NS | 1.271 (0.704-2.294) | ||
Amplification vs Normal | NS | 1.714 (0.771-3.810) | |||
TOB2 | Deletion vs Normal | NS | 1.176 (0.277-4.995) | ||
Amplification vs Normal | NS | 0.945 (0.545-1.641) | |||
ST13 | Deletion vs Normal | NS | 0.913 (0.466-1.788) | ||
Amplification vs Normal | NS | 0.938 (0.500-1.761) | |||
D22S423 | Deletion vs Normal | NS | 1.183 (0.667-2.097) | ||
Amplification vs Normal | NS | 0.896 (0.366-2.192) | |||
D22S283 | Deletion vs Normal | NS | 0.793 (0.397-1.585) | ||
Amplification vs Normal | 0.003 | 0.384 (0.202-0.728) | 0.006 | 0.411 (0.217-0.779 ) | |
TIMP3 | Deletion vs Normal | NS | 1.758 (0.527-5.864) | ||
Amplification vs Normal | NS | 0.736 (0.418-1.296) | |||
NF2 | Deletion vs Normal | NS | 0.929 (0.420-2.055) | ||
Amplification vs Normal | NS | 0.621 (0.344-1.122) |
- Citation: Thanasai J, Limpaiboon T, Jearanaikoon P, Bhudhisawasdi V, Khuntikeo N, Sripa B, Miwa M. Amplification of D22S283 as a favorable prognostic indicator in liver fluke related cholangiocarcinoma. World J Gastroenterol 2006; 12(27): 4338-4344
- URL: https://www.wjgnet.com/1007-9327/full/v12/i27/4338.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i27.4338